483
Waylis TherapeuticsWaylis Therapeutics – FDA 483, Feb 12, 2026
Record Details
Waylis Therapeutics LLC in Rahway, NJ, was inspected by the FDA, revealing a significant deficiency in their post-marketing surveillance procedures. The firm lacked written procedures for monitoring and reconciling adverse drug experiences, especially those reported through their patient access and affordability programs for most of their products. This indicates a failure to establish proper processes for handling critical safety information.
- Person
View Company Profile
ID · 44f6c12f-dc1e-4b2f-9214-28dd5f3eb9e7
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.